Malta - English - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - mianserin hydrochloride - film-coated tablet - mianserin hydrochloride 30 mg - psychoanaleptics

Bangladesh - English - DGDA (Directorate General of Drug Administration)

square pharmaceuticals plc, gazipur - olanzapine - odt tablet - 5 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

square pharmaceuticals plc, gazipur - olanzapine - odt tablet - 10 mg

Malta - English - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - film-coated tablet - mianserin hydrochloride 10 mg - psychoanaleptics

Israel - English - Ministry of Health

unipharm ltd, israel - desipramine hydrochloride - dragee - desipramine hydrochloride 25 mg - desipramine - desipramine - treatment of depression.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

catalysis, s.l. - extracto de ginkgo (ginkgo biloba l - extracto de ginkgo (ginkgo biloba l.)....180,00 mg / citrato de magnesio....65,00 mg / l-arginina....65,00 mg / lactobacillus acidophilus....50,00 mg / Ácido mÁlico....30,00 mg / l-carnitina (como l-carnitina fumarato)....30,00 mg / vitamina c (Ácido l-ascÓrbico)....20,00 mg / Ácido lipoico....10,00 mg / vitamina b6 (clorhidrato de piiridoxina)....0,67 µg / Ácido fÓlico (Ácido pteroilmonoglutÁmico)....66,67 µg / selenito de sodio....40,00 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sun naturals, united states - capsule - 500 mg - st.john's wort

Australia - English - Department of Health (Therapeutic Goods Administration)

luye pharma australia pty ltd - quetiapine fumarate, quantity: 57.56 mg (equivalent: quetiapine, qty 50 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium citrate dihydrate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide; iron oxide yellow; iron oxide red - sequase xr is indicated for: bipolar disorder - maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes - treatment of depressive episodes associated with bipolar disorder (see dosage and administration) - treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. efficacy of sequase xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine ir. schizophrenia: treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder: treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder: treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 345.36 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; hypromellose; titanium dioxide; macrogol 400; povidone - bipolar disorder, adults maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes, treatment of depressive episodes associated with bipolar disorder (see dosage and administration), treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate, children/adolescents aged 10 to 17 years, monotherapy treatment of acute mania associated with bipolar i disorder, schizophrenia (adults and adolescents aged 13 to 17 years), treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 230.24 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; povidone; titanium dioxide; hypromellose; macrogol 400; magnesium stearate; calcium hydrogen phosphate dihydrate - bipolar disorder, adults maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes, treatment of depressive episodes associated with bipolar disorder (see dosage and administration), treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate, children/adolescents aged 10 to 17 years, monotherapy treatment of acute mania associated with bipolar i disorder, schizophrenia (adults and adolescents aged 13 to 17 years), treatment of schizophrenia